Concepedia

Author

Stephen G. O’Brien

Newcastle University

Also Known As

Stephen G O'Brien, Stephen G O'Brien, MD, Stephen G O’Brien, Stephen G. O'Brien, Stephen G. O’Brien

59

Publications

13.6K

Citations

27

H-Index

10

Concepts

All Affiliations

Newcastle UniversityNovartis (Switzerland)University of ChicagoOregon Health & Science UniversityCentre Hospitalier Universitaire de Poitiers
SG

About

Stephen G. O’Brien is an author at Newcastle University specializing in oncology, hematology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

353

2

Health Sciences

2

2

232

3

Pharmacology

2

2

306

4

Pathology

1

1

47

5

Clinical Trials

1

1

185

Stephen G. O’Brien

×

28

Publications

12.7K

Citations

24

H-Index

YearCitations

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson,

New England Journal of Medicine

2003

3.5K

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien,

New England Journal of Medicine

2006

3.5K

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus, Richard A. Larson, François Guilhot,

New England Journal of Medicine

2017

1.2K

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann,

Blood

2007

742

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian Druker, François Guilhot,

Blood

2008

631

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael W. Deininger, Stephen G. O’Brien, François Guilhot,

Blood

2009

615

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford,

Blood

2010

481

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Philipp le Coutre, Oliver G. Ottmann, Francis J. Giles,

Blood

2007

291

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles L. Sawyers,

Blood

2007

208

Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study

Elizabeth A. Hahn, G. Alastair Glendenning, Mark Sorensen,

Journal of Clinical Oncology

2003

208

Page 1